Article Cited by others

INVITED REVIEW

Bone targeted therapies for the prevention of skeletal morbidity in men with prostate cancer

Saylor Philip J

Year : 2014| Volume: 16| Issue : 3 | Page no: 341-347

   This article has been cited by
 
1 The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer
Peter S. Kirk,Tudor Borza,Vahakn B. Shahinian,Megan E.V. Caram,Danil V. Makarov,Jeremy B. Shelton,John T. Leppert,Ryan M. Blake,Jennifer A. Davis,Brent K. Hollenbeck,Anne Sales,Ted A. Skolarus
BJU International. 2017;
[Pubmed]  [Google Scholar] [DOI]
2 Évaluation de la réponse métabolique en TEP/TDM à la F18-FCH après un mois de traitement par acétate d’abiratérone chez les patients présentant un cancer de la prostate métastatique résistant à la castration
S. Boughdad,S. Le Moulec,C. Massard,F. Farace,P. Vielh,O. Aupée,D. Métivier,L. Védrine,E. Gontier
Médecine Nucléaire. 2015; 39(4): 386
[Pubmed]  [Google Scholar] [DOI]
3 Hydrogen Bonding and Anticancer Properties of Water-Soluble Chiralp-Cymene RuIICompounds with Amino-Oxime Ligands
Yosra Benabdelouahab,Laura Muñoz-Moreno,Malgorzata Frik,Isabel de la Cueva-Alique,Mohammed Amin El Amrani,María Contel,Ana M. Bajo,Tomás Cuenca,Eva Royo
European Journal of Inorganic Chemistry. 2015; 2015(13): 2295
[Pubmed]  [Google Scholar] [DOI]
4 Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone
P. D. Ottewell,N. Wang,J. Meek,C. A. Fowles,P. I. Croucher,C. L. Eaton,I. Holen
Endocrine Related Cancer. 2014; 21(5): 769
[Pubmed]  [Google Scholar] [DOI]

 

Read this article